Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Dec 28;18(48):7371-7.
doi: 10.3748/wjg.v18.i48.7371.

Itopride therapy for functional dyspepsia: a meta-analysis

Xuan Huang  1 , Bin Lv, Shuo Zhang, Yi-Hong Fan, Li-Na Meng
Affiliations
Meta-Analysis

Itopride therapy for functional dyspepsia: a meta-analysis

Xuan Huang et al. World J Gastroenterol. .

Abstract

Aim: To evaluate the therapeutic effects of itopride vs other drugs (placebo, domperidone, mosapride) for functional dyspepsia (FD).

Methods: Randomized controlled trials (RCTs) of itopride for FD were retrieved from databases. Relevant information was extracted and analyzed, using the relative risk (RR) and weighted mean deviation, as appropriate. A random or fixed effect model was used, based on the heterogeneity of the included articles, and visual inspection of funnel plots was used to evaluate publication bias.

Results: Nine RCTs enrolling 2620 FD cases were included; 1372 cases received itopride treatment and 1248 cases received placebo or other drugs (control groups). Compared with control groups, itopride had superior RR values of 1.11 [95%CI: (1.03, 1.19), P = 0.006], 1.21 [95%CI: (1.03, 1.44), P = 0.02], and 1.24 [95%CI: (1.01, 1.53), P = 0.04] for global patient assessment, postprandial fullness, and early satiety, respectively. For the Leeds Dyspepsia Questionnaire score, the weighted mean deviation was -1.38 [95%CI: (-1.75, -1.01), P < 0.01]. The incidence of adverse effects was similar in the itopride and control groups. The funnel plots for all indicators showed no evidence of publication bias.

Conclusion: Itopride has good efficacy in terms of global patients assessment, postprandial fullness, and early satiety in the treatment of patients with FD and shows a low rate of adverse reactions. Itopride can greatly improve FD syndromes-score.

Keywords: Functional dyspepsia; Itopride; Meta-analysis; Prokinetic agents; Randomized controlled trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of article inclusion and screening. RCT: Randomized controlled trial.
Figure 2
Figure 2
Forest plot for global patient assessment (A), postprandial fullness (B) and adverse reactions (C) with itopride treatment for functional dyspepsia.
See this image and copyright information in PMC

References

    1. Miwa H, Ghoshal UC, Gonlachanvit S, Gwee KA, Ang TL, Chang FY, Fock KM, Hongo M, Hou X, Kachintorn U, et al. Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil. 2012;18:150–168. - PMC - PubMed
    1. Kwan AC, Bao T, Chakkaphak S, Chang FY, Ke M, Law NM, Leelakusolvong S, Luo JY, Manan C, Park HJ, et al. Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample. J Gastroenterol Hepatol. 2003;18:796–802. - PubMed
    1. Mahadeva S, Yadav H, Everett SM, Goh KL. Economic impact of dyspepsia in rural and urban malaysia: a population-based study. J Neurogastroenterol Motil. 2012;18:43–57. - PMC - PubMed
    1. Mahadeva S, Goh KL. Burden of Dyspepsia in Rural and Urban Asia: Author’s Reply. J Neurogastroenterol Motil. 2012;18:230. - PMC - PubMed
    1. Talley NJ, Tack J, Ptak T, Gupta R, Giguère M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut. 2008;57:740–746. - PubMed

Publication types